Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $29.4 million.

  • SAB Biotherapeutics' Cash & Equivalents rose 21983.38% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 21983.38%. This contributed to the annual value of $8.9 million for FY2024, which is 8426.98% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Cash & Equivalents of $29.4 million as of Q3 2025, which was up 21983.38% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Cash & Equivalents ranged from a high of $56.6 million in Q4 2023 and a low of $2.4 million during Q3 2023
  • Its 5-year average for Cash & Equivalents is $16.0 million, with a median of $13.1 million in 2023.
  • The largest annual percentage gain for SAB Biotherapeutics' Cash & Equivalents in the last 5 years was 27930.64% (2024), contrasted with its biggest fall of 8426.98% (2024).
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Cash & Equivalents stood at $33.2 million in 2021, then crashed by 54.69% to $15.0 million in 2022, then skyrocketed by 275.93% to $56.6 million in 2023, then crashed by 84.27% to $8.9 million in 2024, then soared by 230.69% to $29.4 million in 2025.
  • Its Cash & Equivalents stands at $29.4 million for Q3 2025, versus $3.7 million for Q2 2025 and $5.6 million for Q1 2025.